May 6, 2020

Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response

Logo of ebiomGuide for AuthorsAboutExplore this JournalEBioMedicine

Associated Data

Supplementary Materials

Abstract
Background
BM32, a grass pollen allergy vaccine containing four recombinant fusion proteins

Application of probiotics in adjuvant treatment of infant allergic rhinitis

RESEARCH ARTICLE: STUDY PROTOCOL CLINICAL TRIAL
A randomized controlled study

Cao, Xueqiu MDa,b; Zhong, Ping MDa; Li, Gang MDa; Zhu, Jiao MDa; Zheng, Yun PhDa,∗Author Information
Medicine: May 2020 - Volume 99 - Issue 18 - p e20095
doi: 10.1097/MD.0000000000020095
  • OPEN
Abstract
Background:

Several studies have suggested that intestinal flora may play an important role in allergic diseases. The purpose of this study was to investigate the effect of probiotics of Bifidobacterium triplex on the symptoms of allergic rhinitis (AR).

May 4, 2020

Clinical trials in allergen immunotherapy in the age group of children and adolescents: current concepts and future needs

  • Review
  • Open Access

Clinical and Translational Allergy
Abstract
Allergen immunotherapy (AIT) is the only treatment option available for allergic patients with disease-modifying intention. Both efficacy and safety has been demonstrated for multiple trials in children, adolescents and adults. Though regulatory requirements for marketing authorization have been clearly outlined and an increasing number of high quality trials has been initiated, multiple concepts and details in study design may be further elaborated, harmonized and improved.

April 24, 2020

Prognostic factors for ARDS: clinical, physiological and atypical immunodeficiency

Abstract
Background
Relationships between the lymphocyte/neutrophil ratio and age,
APACHE II score, SOFA score, and PaO
2/FiO2 ratio in ARDS patients
Risk factors affecting the prognosis of acute respiratory distress syndrome (ARDS) in adults were investigated. The aim was to identify new predictors for ARDS patient prognosis, including those with clinical, pathophysiological, and atypical immunodeficiency.
Methods
ARDS patients were retrospectively included. The patients were grouped and analysed according to different oxygenation index grades and prognosis, and factors influencing prognosis and survival were examined. Adolescent patients, patients with typical immunodeficiency and patients who died within 24 h after being diagnosed with ARDS were excluded. The predictive value for mortality was determined by Cox proportional hazard analysis.

April 22, 2020

Systemic Immunomodulatory Treatments for Patients With Atopic Dermatitis

Key Points
Network Graphs of Studies Included in the Analysis of
Atopic Dermatitis Treatment Between 8 and 16 Weeks
Question  What is the relative effectiveness of systemic treatments for patients with atopic dermatitis?
Findings  This network meta-analysis of 39 randomized clinical trials including 6360 patients found that dupilumab and cyclosporine were similarly effective for adult patients with atopic dermatitis for up to 16 weeks of treatment and were more effective than methotrexate and azathioprine.
Meaning  Cyclosporine and dupilumab may have better short-term effectiveness than methotrexate and azathioprine for patients with atopic dermatitis; this analysis will be updated to add evidence as new medications are approved.

Impact on quality of life and safety of sublingual and subcutaneous immunotherapy in children with severe house dust mite and pollen-associated allergic rhinoconjunctivitis

Abstract

Background
Pollen and house dust mite (HDM) subcutaneous immunotherapy (SLIT) and pollen subcutaneous immunotherapy (SCIT) are effective therapies for children with allergic rhinoconjunctivitis (AR). There are no previous direct comparative studies investigating quality of life (QoL) of all three immunotherapy regimes. The aim of this study was to compare QoL and safety in children receiving these immunotherapies for AR.

April 18, 2020

CME: Differentiating EGPA from Other Eosinophilic Disorders


Healio

CME: Differentiating EGPA from Other Eosinophilic Disorders
This activity is supported by an educational grant from GlaxoSmithKline. 

CREDITS: 0.25 CME EXPIRES: 3/29/2021 | MINS: 15 | FEE: $0


Activity Description

In this case-based video, Leonard Calabrese, DO, and Curry Koening, MD, MS, discuss the immunopathology and clinical features of eosinophilic granulomatosis with polyangiitis (EGPA), providing guidance on differentiating EGPA from related vasculitides or eosinophilic conditions.

April 16, 2020

The influence of chlorine in indoor swimming pools on the composition of breathing phase of professional swimmers

  • Research
  • Open Access

Abstract
Objectives
Swimming is one of the most popular forms of physical activity. Pool water is cleaned with chlorine, which - in combination with compounds contained in water - could form chloramines and trichloromethane in the swimmer’s lungs. The aim of the present study was to examine the effect of swimming training in an indoor pool on the composition of swimmers’ respiratory phase metabolomics, and develop a system to provide basic information about its impact on the swimmer’s airway mucosa metabolism, which could help to assess the risk of secondary respiratory tract diseases i.e. sport results, condition, and health including lung acute and chronic diseases).